Heterologous Chimeric Construct Comprising a Modified Bacterial Superantigen and a Cruzipain Domain Confers Protection Against Trypanosoma cruzi Infection

Maria Belén Antonoglou1,2, Andrés Sánchez Alberti1,2,3, Daniela Maria Redolfi1,2, Augusto Ernesto Bivona1,2,3, Maria Julieta Fernández Lynch1,2, Sofia Noli Truant1,2, Maria Belén Sarratea1,2, Laura Valeria Iannantuono López2, Emilio Luis Malchiodi1,2,3 and Marisa Mariel Fernández1,2*

1 Cátedra de Inmunología, Departamento de Microbiología, Inmunología, Biotecnología y Genética, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina, 2 Instituto de Estudios de la Inmunidad Humoral “Prof. Ricardo A. Margni” (IDEHU), UBA-CONICET, Universidad de Buenos Aires, Buenos Aires, Argentina, 3 Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina and Instituto de Microbiología y Parasitología Médica (IMPaM), UBA-CONICET, Universidad de Buenos Aires, Buenos Aires, Argentina

Chagas disease is an endemic chronic parasitosis in Latin America affecting more than 7 million people. Around 100 million people are currently at risk of acquiring the infection; however, no effective vaccine has been developed yet. Trypanosoma cruzi is the etiological agent of this parasitosis and as an intracellular protozoan it can reside within different tissues, mainly muscle cells, evading host immunity and allowing progression towards the chronic stage of the disease. Considering this intracellular parasitism triggers strong cellular immunity that, besides being necessary to limit infection, is not sufficient to eradicate the parasite from tissues, a differential immune response is required and new strategies for vaccines against Chagas disease need to be explored. In this work, we designed, cloned and expressed a chimeric molecule, named NCz-SEG24A, comprising a parasite antigen, the N-terminal domain of the major cysteine protease of T. cruzi, cruzipain (Nt-Cz), and a non-toxic form of the staphylococcal superantigen (SAg) G, SEG, with the residue Asn24 mutated to Ala (N24A). The mutant SAg SEG24A retains its ability to trigger classical activation of macrophages without inducing T cell apoptosis. To evaluate, as a proof of concept, the immunogenicity and efficacy of the chimeric immunogen vs. its individual antigens, C3H mice were immunized intramuscularly with NCz-SEG24A co-adjuvanted with CpG-ODN, or the recombinant proteins Nt-Cz plus SEG24A with the same adjuvant. Vaccinated mice significantly produced Nt-Cz-specific IgG titers after immunization and developed higher IgG2a than IgG1 titers. Specific cell-mediated immunity was assessed by in-vivo DTH and significant responses were obtained. To assess protection, mice were challenged with trypomastigotes of T. cruzi. Both schemes reduced the parasite...
load throughout the acute phase, but only mice immunized with NCz-SEGN24A showed significant differences against control; moreover, these mice maintained 100% survival. These results encourage testing mutated superantigens fused to specific antigens as immune modifiers against pathogens.

Keywords: cruzipain, chimeric immunogen, immune modulators, Trypanosoma cruzi, mutant superantigen

INTRODUCTION

Pathogens have evolved a diverse range of strategies to subvert the host immune system and survive. These strategies include evasion and modulation of the immune response, among others. Most of the intracellular parasites constitute a perfect example of this situation. Trypanosoma cruzi is the intracellular protozoan that causes Chagas disease, which affects 7 million people in America (1, 2) and leaves 100 million people in endemic areas at risk of acquiring the infection (3). The infection is contracted when the infective form of the parasite, the metacyclic trypomastigote, presents in the feces of hematophagous triatomines and penetrates a skin wound or an intact mucosa of the host. The acute phase of the disease exhibits non-specific symptoms, except for a periorbital eye inflammation denominated Romaña’s sign, which usually occurs when the inoculation site is the conjunctiva. Although an important immune response is detected during this phase, it is inefficient to eradicate the parasite, allowing the development of the disease chronic period, which extends for decades. This stage is characterized by a low or undetectable parasitemia and most of the patients remain asymptomatic. After this period, around 30% of the infected people develop serious cardiac or digestive pathologies (4, 5). In addition to the worsening of the health, Chagas disease has also a high economic impact since it mostly affects economically active people (6). With the aim to develop an effective vaccine against T. cruzi to prevent or treat the infection, many antigens have been tested in preclinical studies in combination with different adjuvants [Reviewed in Cazorla et al. (7)]. In many of these studies, after experimental challenge vaccinated mice achieved 100% survival rates; however, clinical trials in humans were not performed with these formulations. In the last 20 years, recombinant proteins or DNA were employed as immunogens and, in combination with the latest generation of adjuvants, new vaccination strategies were developed with promising results [Reviewed in Bivona et al. (8)]. Cruzipain (Cz), the major cysteine protease of T. cruzi, has been studied by many authors as a fine antigen to evoke protective immune responses (9–16). In 2010, Cazorla et. al. described that the N-terminal domain of Cz (Nt-Cz) displayed the highest protective role during immunization, bypassing ineffective responses towards the C-terminal domain (17). In previous work from our laboratory, an engineered chimeric immunogen named Traspain was designed containing Nt-Cz as one of the key parasitic molecules, with very promising results (18, 19).

The development of effective prophylactic or therapeutic vaccines against T. cruzi requires the use of adjuvants and diverse delivery systems which promote a differential immune response. Bacterial Superantigens (SAgs) are enterotoxins which engage the T cell receptors (TCR) on the surface of T cells and the major histocompatibility complex (MHC) class II molecules on antigen presenting cells (APC) as non-processed molecules, eliciting an unregulated immune response characterized by a strong proinflammatory profile and a non-effective immune response. The idea of using this important immune modulatory characteristic of the SAgs for health care, gave rise to the construction of biotherapeutic tools for cancer treatment (20–22). Based on the capacity of SAgs to induce cross-presentation, modified SAgs were also used as adjuvants to improve the vaccination process (23).

The staphylococcal enterotoxin G (SEG) is a non-classical SAg which belongs to the group II or SEB family (24, 25). In the absence of T cells, SEG interacts with human monocyctic/macrophagic cells inducing a strong M1 immune response with proinflammatory cytokines, which would eventually lead to a further T cell differentiation toward Th1/Th17 profiles (26). SAgs are also able to interact with dendritic cells without affecting their viability or migration to the secondary lymphoid organs. In a previous study (27), we demonstrated that SEG is phagocytized by murine dendritic cells, is found in sequential vesicles and afterwards released in the lymph node as a native and active molecule able to interact with TCR and MHC-II.

SAgs can stimulate T cells bearing certain variable β chain isotypes. The SAgs of group II are very well-characterized by their interaction with the mouse variable β chain 8.2 (mVβ). Classical SAgs, such as SEB and SEC3, bind the mVβ8.2 chain establishing three hydrogen bonds with residues located in the β chain through Asn24, with an affinity in the micromolar range. The affinity between SEG and mVβ8.2, which is in the nanomolar range, is the highest reported for staphylococcal superantigens (28). The complex SEG-Vβ8.2 has been crystallized, and the residues involved in the direct contact between these molecules are very well-documented (29). As it was also described for classical SAgs, the Asn24 on SEG surface is crucial for the interaction with the TCR and promotion of the T cell proliferation and further exhaustion (30).

These previous works prompted us to develop a mutant version of SEG, SEG24A, which would be non-toxic but would maintain SAg's properties at innate level without exhaustion of the T cell responses. In addition, we designed, expressed, and tested as a proof of concept, a heterologous chimeric immunogen between the mutated bacterial SAg, SEG24A, and the N-terminal domain of the major parasite antigen, Cz, with the aim to control T. cruzi infection in mice. The idea behind the
design was that SEGN24A would contribute with its immune modulatory properties at the innate immune response, while Nt-Cz would confer specific protection to the immunized host. We demonstrated that the chimeric antigen, named NCz-SEGN24A adjuvanted with CpG-ODN, was able to protect against infection with T. cruzi, improving the performance of the administration of non-conjugated Nt-Cz and SEGN24A antigens.

**MATERIALS AND METHODS**

**Mice, Parasites and Cells**

Different groups of inbred mice from the C3H/HeN strain were used in this work for immunization protocols. Mice breeding was carried out in the animal facilities of the “Instituto de Microbiología y Parasitología Médica” (IMPaM, UBA, Argentina) and conducted in accordance with the guidelines established by the National Research Council (CONICET), CD resolution #: 3381-18.

*Trypanosoma cruzi* bloodstream trypanomastigotes (from strains RA, Tulahuen-expressing β-galactosidase or K98 clone) were obtained from blood of CF1 infected mice. Vero cells (ATCC CCL-81) were used for *T. cruzi* in-vitro infection and cultured in RPMI-1640 medium (Gibco) supplemented with 10% fetal bovine serum (FBS). RAW 264.7 cells (ATCC TIB-71) were used for evaluation of SAgs-supplemented with 10% fetal bovine serum (FBS). RAW 264.7 cells (ATCC TIB-71) were used for evaluation of SAgs-supplemented with 10% FBS. Both cell lines were regularly tested for *Mycoplasma* spp. infection with DAPI staining.

**Superantigens and Nt-Cz Recombinant Expression and Purification**

Staphylococcal SEGwt was produced and purified as previously described (28). Briefly, SEGwt was cloned in pET-26b (Novagen, Merck), expressed in *Escherichia coli* BL21 (DE3) and purified by Ni⁺⁺-NTA affinity chromatography (GE Healthcare), followed by Superdex 200 molecular exclusion (GE Healthcare).

Hot spot punctual mutation on the TCR-binding site of SEGwt was introduced by site-directed mutagenesis (QuickChange™ Site-Directed Mutagenesis Kit, Stratagene). Asn24, which is essential for TCR binding and T cell activation (29), was replaced by Ala, generating the mutant SEGN24A. pET-26b plasmid encoding the seg24a gene was used to transform competent *E. coli* BL21 (DE3). SEGN24A protein was expressed in *E. coli* BL21 (DE3) as inclusion bodies, in-vitro refolded by drip dialysis method and further purified under native conditions by Ni⁺⁺-NTA.

The N-terminal domain of Cz (Nt-Cz) was produced as previously described (17). Briefly, Nt-Cz was cloned in pET-23a, expressed in *Escherichia coli* BL21 (DE3) and purified by Ni⁺⁺-NTA affinity chromatography, followed by in-vitro-folding by dialysis. Purity levels of proteins were determined by SDS-PAGE.

Proteins were treated with agarose-polymixin B (Sigma Aldrich) to remove endotoxin traces and absence of LPS was assessed by Limulus test. In addition, the amount of remaining endotoxin was evaluated by the Pierce LAL chromogenic endotoxin quantitation Kit (Thermo Scientific) following the manufacturers' instructions. For all recombinant proteins, it was verified that <0.1 EU/ml of endotoxin was present.

**Flow Cytometry for in-vivo Stimulation of T Cells Bearing TCR Vβ8.1/8.2**

Female C3H/HeN mice 6 to 8 weeks-old (*n* = 3/group) were inoculated subcutaneously into the footpad with 30 µg of SEGwt or SEGN24A, or sterile PBS (control). After 48 h, mice were sacrificed, and their popliteal and inguinal lymph nodes were removed. Single cell suspensions were obtained from each node by mechanical dislodging. Cells were immunolabeled with e-Fluor 660-conjugated anti-mouse CD3 antibody (e-Bioscience Inc.) and FITC-conjugated anti-Vβ8.1/8.2 TCR (e-Bioscience, Inc.). To perform suitable data acquisition and analysis, autofluorescence and single-stained controls were included. Stained cells were passed through the BD FACSCanto flow cytometer. Data were analyzed using the FlowJo v10 software (Tree Star, Inc.).

**Surface Plasmon Resonance Assay (SPR)**

SPR assays were performed using a BIACore T100 instrument (GE Healthcare). SEGwt or SEGN24A (ligands) were immobilized on a CM5 chip (GE Healthcare) surface by amine coupling according to the manufacturer's instructions. Soluble TCR β chain Vβ8.2 protein (analyte) was diluted in PBS, pH 7.4 running buffer, and injected over chip surfaces at a flow rate of 30 µl x min⁻¹ for 60 s at 25°C. The data were analyzed with the BIA evaluation software (GE Healthcare). To avoid conformational restrictions due to the immobilization procedure, the assay was also performed immobilizing TCR β chain Vβ8.2 over the chip surface and using SEGwt or SEGN24A as analyte (31).

**Cell Inhibition Assays**

To evaluate the ability of SAgs to inhibit macrophage proliferation, RAW 264.7 cells (2 x 10⁴/well) were cultured in the presence of SEGwt, SEGN24A (10 µg/ml) or medium (control) for 48 h at 37°C in 5% (v/v) CO₂. During the last 8 h, 0.5 µCi [³H]-thymidine/well was added and then harvested onto glass fiber filters. Incorporation of radioactivity was then measured using a Liquid Scintillation Analyzer Tri-Carb 2810 TR (Perkin Elmer). All measurements were made in triplicate.

**Nitrite Assay**

Nitrites production was evaluated in culture supernatants by Griess reaction. Briefly, RAW 264.7 cells (1 x 10⁵/well) were cultured in the presence of SEGwt, SEG24A (10 µg/ml) or medium (control). At 48 h supernatants were recovered, mixed with same volume of A + B Griess reagent (Laboratorios Britania) and then incubated in the dark for 10 min at room temperature.

The absorbance of the reaction mixture was measured at 540 nm and the nitrites concentration in the samples was determined using a sodium nitrite (NaNO₂) standard curve.
NCz-SEGN24A Construction, Recombinant Expression and Characterization

The heterologous chimeric *ncz-segn24a* gene was constructed using splicing by overlap extension PCR (SOE-PCR) (32, 33). Supplementary Figure 1 provides details on the PCRs that were performed in order to fuse *nt-cz* and *segn24a* genes. The resultant fused chimeric gene was *ncz-segn24a*. BamHI restriction site was included in *Pf1* and *Pr4* included EcoRI restriction site as well as a 6 his tag coding sequence. Cloning was done in a pET-32a(+) vector, which allowed fusion to thioredoxin (Trx). Gene sequencing was performed to confirm the chimeric gene.

NCz-SEGN24A (MW 69 kDa) protein was expressed in *E. coli* BL21 (DE3) as inclusion bodies, purified under denaturing conditions by Ni**+**+-NTA, *in vitro* refolded by dialysis method and further purified by Superdex 200 molecular exclusion (GE Healthcare). Purity levels were determined by SDS-PAGE. LPS absence was determined by the Pierce LAL chromogenic endotoxin quantitation Kit (Thermo Scientific) following the manufacturers’ instructions.

Immunoblotting was performed in order to verify NCz-SEGN24A identity. Briefly, 10 µg of NCz-SEGN24A, NT-Cz (MW 23 kDa) and SEGN24A (MW 27 kDa) were separated by 12.5% SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membrane. As primary antibodies, sera from mice immunized with the recombinant protein NT-Cz or SEG superantigen were used (1/500 dilution). As secondary antibody, rabbit anti-mouse IgG conjugated with horseradish peroxidase (Jackson ImmunoResearch), or biotin-conjugated anti-mouse IgG1 or anti-mouse IgG2a (Pharmingen Becton Dickinson), were used as secondary antibodies.

Immunization Protocols

As a proof of concept, different immunization protocols were tested in this work. Inbred C3H/HeN mice from 6 to 8 weeks old (n = 5-6 animals per group) were used. In all cases, animals were immunized with 4 doses of each formulation separated by 15 days, intramuscularly in the quadriceps muscles.

To initially prove properties of NCz-SEGN24A as an immunogen, two experimental groups were designed: (i) 10 µg of recombinant protein NCz-SEGN24A and (ii) control with PBS (control group in each protocol).

Secondly, the chimeric protein was proved in parallel with its individual antigens, using the adjuvant CpG-ODN 1826 (Invivogen). In this case, three experimental groups were designed: (i) NCz-SEGN24A protein+CpG, (ii) NT-Cz protein+SEGN24A+CpG, (iii) control. Each group received 10 µg of each component, with the exception of group (ii) that received 5 µg of each antigen.

In the last part of this work, NCz-SEGN24A was evaluated against the single *T. cruzi* specific antigen; in order to achieve this, three experimental groups were immunized: (i) NCz-SEGN24A protein+CpG, (ii) NT-Cz protein+CpG, (iii) control. Each group received 10 µg of each component.

ELISA for Determination of Antigen-Specific IgG Antibodies

Sera from immunized mice were collected 15 days after the last dose for the determination of antigen-specific IgG, IgG1, IgG2a by indirect ELISA, as previously described (34). Plates were coated with Nt-Cz protein in all cases, and horseradish peroxidase-labeled anti-mouse IgG antibody (Jackson ImmunoResearch), or biotin-conjugated anti-mouse IgG1 or anti-mouse IgG2a (Pharmingen Becton Dickinson), were used as secondary antibodies.

Cell Infection Inhibition by Specific Immune Sera

The ability of sera from immunized mice to inhibit parasite infection was assessed. Vero cells (5 × 10⁵ cells/well) were infected with blood trypomastigotes expressing β-galactosidase at a MOI of 10:1 for 24 h at 37°C. Tryptomastigotes were pre-incubated in triplicate with diluted serum (1/10) from mice immunized with NCz-SEGN24A+CpG. After overnight incubation, cells were washed and treated for 4 days. CPRG was added to determine the levels of parasites as previously described (35). Uninfected cells were used as blanks, and additional controls were performed with sera from mice before immunization (pre-immune) and sera from non-immunized mice.

Delayed-Type Hypersensitivity Test (DTH)

A DTH assay was performed 15 days after the last immunization by intradermal challenge with 10 µg of Nt-Cz in the right footpad of the animals. Footpad thickness was measured before and 72 h after antigen inoculation using a Vernier caliper. Results are expressed as the increased millimeters in footpad thickness induced by inoculation.

Challenge With *T. cruzi* Bloodstream Trypomastigotes

Fifteen days after the last immunization, animals (n = 5-6 per group) were infected intraperitoneally with 10⁴ *T. cruzi* blood trypomastigotes of the virulent RA strain, for analysis of the acute phase. Parasitemia was monitored by counting blood parasites every 2–3 days in a Neubauer chamber. For this purpose, a 1/5 dilution of blood in lysis buffer (0.75% NH₄Cl, 0.2% Tris, pH 7.2) was made.

Alternatively, vaccine efficacy was evaluated in a sub-lethal challenge. For this purpose, after the last immunization animals were challenged with 3 × 10⁵ blood trypomastigotes of the less virulent K98 clone (from CA-I strain) by intraperitoneal injection. Parasitemias were recorded weekly during the acute phase (19, 35).

Statistical Analysis

Statistical analysis was carried out with GraphPad Prism 6.0 software (San Diego, CA, USA), using one-way or two-way ANOVA along with the post-tests indicated in each trial, unless otherwise specified in figure legends.

The statistical analyses were referred to the control group of each experiment, except when indicated. Values of p < 0.05 were considered significant.
RESULTS

Mutant SEGN24A Neither Binds Mouse TCR Variable β Chain nor Stimulates in-vivo Vβ8.1/8.2 Bearing T Cells

Taking into account the high resolution X-ray structure of SEGwt-mVβ8.2 (pdb 3MC0) as a template (29), selective mutation of Asn24, crucial residue for binding to the TCR in related SAggs (30), resulted in the generation of SEGN24A. Structural studies strongly suggested that higher affinity of SEG-mVβ8.2 complex is due to the presence of five hydrogen bonds established between SEGN24 and different residues of the TCR variable β chain. Due to the nature of the Ala side chain, hydrogen bonds cannot be established with the TCR residues since they are outside of the interaction sphere (distances higher than 3.4 Å) (Figure 1A). In order to evaluate the resultant ability of mutant SEGN24A to bind mVβ8.2 chain, surface plasmon resonance (SPR) assays were performed. Direct binding of soluble SEGwt or SEGN24A to mVβ8.2 was analyzed. SEGN24A failed to bind mVβ8.2 specifically. On the contrary, the interaction between SEGwt and mVβ8.2 showed a high affinity with a dissociation constant (K_D) of $3.7 \times 10^{-7}$ M (Figure 1B), in accordance with our previous results (29).

We next analyzed whether SEGN24A would be able to induce stimulation of T cells bearing Vβ8.1/8.2 in-vivo. SEGwt and SEGN24A were subcutaneously injected into C3H mice footpad. After 48 h, mice were sacrificed, and their popliteal and inguinal lymph nodes removed and pooled for analysis of Vβ8.1/8.2 T cell populations. FACS analysis showed a significant increase in the frequency of Vβ8.1/8.2$^+$ T cells in lymph nodes stimulated with SEGwt, while SEGN24A was unable to stimulate Vβ8.1/8.2$^+$ T cells (Figure 1C).

**Figure 1** | Superantigen mutant SEGN24A shows no effect on T cells but retains ability to induce a proinflammatory profile in RAW 264.7 macrophages. (A) Comparison of the TCR mVβ8.2 and SEGwt (pdb 1XXG) or SEGN24A interfaces. mVβ8.2 and SEG are colored wheat and magenta, respectively. Residues of mVβ8.2 involved in the interaction with residue 24 of SEGwt or SEGN24A are colored green. SEG N24 (left side) or A24 (right side) are colored cyan or white, respectively. Hydrogen bonds established between Asn24 and mVβ8.2 are shown as black dashes. Since hydrogen bonds must be calculated with a cut-off distance of 2.5–3.4 Å, Ala24 is not able to establish hydrogen bonds with mVβ8.2. (B) SPR analysis of SEG-mVβ8.2 interaction. SPR sensorgrams show the interactions between SEGwt (800 RU immobilized, lower panel) with mVβ8.2 (1.50–0.09 µM), or SEGN24A (900 RU immobilized, upper panel) with mVβ8.2 (60–0.8 µM) after correction for nonspecific binding. Apparent K_D for binding of mVβ8.2 to immobilized SEGwt was $3.7 \times 10^{-7}$ M by kinetic analysis using a 1:1 binding model. SEGN24A showed no specific binding to mVβ8.2. (C) C3HHeN mice were inoculated subcutaneously with 30 µg of SEGwt, SEGN24A or PBS (control) into the mice footpad. After 48 h, cells were isolated from popliteal and inguinal lymph nodes and T cell stimulation was evaluated by flow cytometry with anti-CD3$^+$ and anti-Vβ8.1/8.2$^+$.

Frontiers in Immunology | www.frontiersin.org 5 June 2020 | Volume 11 | Article 1279

**Figure 1** | Superantigen mutant SEGN24A shows no effect on T cells but retains ability to induce a proinflammatory profile in RAW 264.7 macrophages. (A) Comparison of the TCR mVβ8.2 and SEGwt (pdb 1XXG) or SEGN24A interfaces. mVβ8.2 and SEG are colored wheat and magenta, respectively. Residues of mVβ8.2 involved in the interaction with residue 24 of SEGwt or SEGN24A are colored green. SEG N24 (left side) or A24 (right side) are colored cyan or white, respectively. Hydrogen bonds established between Asn24 and mVβ8.2 are shown as black dashes. Since hydrogen bonds must be calculated with a cut-off distance of 2.5–3.4 Å, Ala24 is not able to establish hydrogen bonds with mVβ8.2. (B) SPR analysis of SEG-mVβ8.2 interaction. SPR sensorgrams show the interactions between SEGwt (800 RU immobilized, lower panel) with mVβ8.2 (1.50–0.09 µM), or SEGN24A (900 RU immobilized, upper panel) with mVβ8.2 (60–0.8 µM) after correction for nonspecific binding. Apparent K_D for binding of mVβ8.2 to immobilized SEGwt was $3.7 \times 10^{-7}$ M by kinetic analysis using a 1:1 binding model. SEGN24A showed no specific binding to mVβ8.2. (C) C3HHeN mice were inoculated subcutaneously with 30 µg of SEGwt, SEGN24A or PBS (control) into the mice footpad. After 48 h, cells were isolated from popliteal and inguinal lymph nodes and T cell stimulation was evaluated by flow cytometry with anti-CD3$^+$ and anti-Vβ8.1/8.2$^+$. (D) RAW 264.7 cells (2 x 10^5 well) were incubated with wild-type or mutant superantigens (10 µg/ml) for 48 h, 0.5 µCi [3H]-thymidine/well was added for the last 8 h. DNA was harvested and counts per minute were determined as a measure of cell proliferation. (E) Supernatants of RAW 264.7 cells (1 x 10^6/well) were collected after 48 h of stimulation with SAggs and the nitrites level was measured using the Griess reagent. Data are expressed as the mean ± SEM of three independent experiments. Asterisks represent statistical significance respect to control. *p < 0.01, **p < 0.001, ***p < 0.0001, ns, non-significant. Hashes represent statistical significance between stimulation with wild-type and mutant SAg, #p < 0.05, ##p < 0.01, ###p < 0.001, ns, non-significant. One-way ANOVA plus Tukey’s post-test (C–E).
SEG24A Retains, in a Lesser Extent, SEGwt Effects on Macrophages

To verify if SEG24A retained the ability to induce a M1 profile on macrophages, a mouse macrophagic cell line RAW 264.7 was cultured in presence of SEG24A or SEGwt. Although in a lesser extent, the mutated SAg was able to mimic the effect of SEGwt. Both wild type and mutant SAGs induced an inhibition of macrophagic proliferation in absence of T cells (Figure 1D). This phenomenon was previously related to apoptotic and necrotic death with an early activation and secretion of proinflammatory cytokines (26). The cell death process would be of interest considering that other adjuvants such as aluminum salts mediate their adjuvant-properties in part through the release of damage associated molecular pattern (DAMPs) after exerting cytotoxicity (36, 37). Moreover, SEG24A induced a significant increment in nitrates production (Figure 1E), characteristic of classical macrophage activation.

These results confirm that while SEG24A has no TCR binding function (Figure 1B), it keeps the ability to interact with macrophagic cells, an essential feature to exert an adjuvant effect.

Construction, Expression and Characterization of the Heterologous Chimeric Antigen NCz-SEG24A

The heterologous chimera between a parasite antigen domain and a bacterial mutated superantigen, NCz-SEG24A, was engineered fusing the Nt-Cz domain directly to the mutant SEG24A. The construct also possesses a thioredoxin N-terminal tag, to facilitate folding and stability due to disulfide bonds formation, and a 6 his tag to allow purification (Figure 2A). NCz-SEG24A was successfully expressed in E. coli BL21 (DE3) and purified by Ni²⁺-NTA affinity chromatography. Refolding of recombinant NCz-SEG24A was performed in-vitro, followed by molecular exclusion chromatography (Figure 2B). A single 69 kDa band was obtained by SDS-PAGE (Figure 2C). Final yield of NCz-SEG24A protein was ~5 mg per liter of culture.

The immunochemical identity of the construct was furthered determined by Western Blot. NCz-SEG24A was recognized by polyclonal antibodies specific for both domains (Figure 2D).

Immunization With NCz-SEG24A Elicits a Humoral and Cellular Specific Immune Response

With the aim to evaluate the immunogenicity of adjuvantless NCz-SEG24A, C3H mice were immunized with four doses of the recombinant protein and 15 days after last boost, Nt-Cz-specific antibody titers in sera were determined by ELISA. We observed that mice immunized with NCz-SEG24A elicited antibody titers considerably higher than control group (p < 0.01) (Figure 3A). To estimate the developed T cell profile, we analyzed the titers of the IgG1 and IgG2a isotypes specific against Nt-Cz. Antibodies isotypes reflected a Th1-biased response since IgG2a levels were higher than IgG1 (p < 0.0001) (Figure 3B).

A delayed-type hypersensitivity test was performed to evaluate the specific cellular immune response. Mice developed a tendency of swelling regarding a cellular response, 72 h after the injection of Nt-Cz in the footpad (0.13 ± 0.03 for NCz-SEG24A vs. 0.07 ± 0.01 for control) (Figure 3C).

These results were encouraging since a parasite homologous chimeric immunogen, Traspain (18), was not able to promote specific humoral or cellular immune responses (Sanchez Alberti, unpublished results).

NCz-SEG24A Immunization Displays a Tendency of Parasite Load Reduction After T. cruzi Challenge

To evaluate if immunization with NCz-SEG24A was able to confer protection, 15 days after last dose mice were challenged with bloodstream trypomastigotes of the K98 clone, from T. cruzi CA-I strain. As it is shown in Figure 3D, immunization with NCz-SEG24A resulted in a reduction of the number of circulating parasites. Furthermore, at the peak of parasitemia (35 dpi) there was a significant reduction of parasites compared against control (PBS) (p<0.05). We also calculated the area under the parasitemia-concentration-time curve (AUC) to assess the ability of the vaccination to reduce the total parasite load. In this case, we observed a reduction of the total parasite load conferred by immunization with NCz-SEG24A, although there was not a significant difference compared to control (AUC: 112.5 ± 36.9 vs. 132.8 ± 41.0, respectively) (Figure 3E).

Co-administration of NCz-SEG24A With CpG-ODN Evokes Specific Humoral Responses and Develops Neutralizing Antibodies

Taking into account the well-known capacity of CpG-ODN to stimulate Th1-responses (38, 39), we combined them with the chimeric NCz-SEG24A. Considering that the protective effect could be due to the administration of one molecule that would function as an immune modulator and another that would serve as the specific immunogenic antigen (40, 41), we also developed an immunization protocol that included the individual proteins Nt-Cz and SEG24A co-administered with CpG-ODN. Immunization groups through the intramuscular route included: Nt-Cz+SEG24A+CpG, or the chimeric NCz-SEG24A+CpG, all the antigens in equal molar mass. Analysis of the specific antibody response obtained after the last dose showed that both groups developed high and significant IgG anti-Nt-Cz specific titers (p < 0.01 and p < 0.05, respectively), which did not differ from each other (Figure 4A). Interestingly, immunization with both, the individual antigens and the chimeric antigen plus CpG-ODN elicited significant IgG2a specific antibodies, reflecting a Th1-biased response (Figure 4B). We observed an unbalanced ratio IgG2a/IgG1 for the immunization with the separated proteins, suggesting a more balanced immunity when NCz-SEG24A plus CpG-ODN is used as immunogen (Figure 4C). As expected, antibodies specific
FIGURE 2 | Construction and characterization of heterologous chimeric antigen NCz-SEG24A. (A) Schematic representation of NCz-SEG24A. Bacterial SAg mutant SEG24A was fused to the C-terminal of the N-terminal domain of parasite cruzipain (Nt-Cz). A thioredoxin (Trx) tag was added to fused NCz-SEG24A in its N-terminal, and histidine tag (His-tag) was added at the C-terminal. (B) Chromatogram of the NCz-SEG24A purification with Superdex 200 molecular exclusion (SEC). (C) Analysis of recombinant NCz-SEG24A by SDS-PAGE. The 69-kDa protein was detected using Coomassie blue staining after purification by Ni²⁺-NTA column followed by SEC (Lane 2). Arrow indicates NCz-SEG24A band. (D) Immunochemical identity by Western blot. Domain-specific polyclonal antibodies were used as primary antibodies. SDS-PAGE gels were loaded as follows, lines: 1- MWM, 2- SEG24A (left, 27 kDa) or Nt-Cz (right, 23 kDa), 3- NCz-SEG24A (69 kDa), arrows point at NCz-SEG24A band.

Titers resulted about 10-fold higher when immunization was performed with CpG-ODN compared to adjuvantless injection (Figure 3A).

More importantly, Nt-Cz-specific antibodies proved to be functional and neutralizing, since incubation of trypomastigotes of Tulahuen strain with serum of NCz-SEG24A-vaccinated mice significantly decreased in-vitro invasion of non-phagocytic Vero cells (Figure 4D).

Moreover, when analyzing cellular in-vivo responses, a significant increase in DTH assay was
observed for both immunization with individual proteins or NCz-SEGN24A ($p < 0.01$ and $p < 0.001$, respectively) (Figure 4E).

**NCz-SEGN24A Plus CpG-ODN but Not Its Individual Antigens Confer Protection Against T. cruzi Challenge**

To determine whether chimeric NCz-SEGN24A adjuvanted with CpG-ODN possessed superior protective capacity against *T. cruzi* infection compared to its individual domains, 2 weeks after immunization mice were challenged with blood trypomastigotes from the virulent RA strain, belonging to the discrete type unit (DTU) TcVI. Throughout the acute phase of the parasitemia, NCz-SEGN24A+CpG showed the ability to reduce the level of circulating parasites (Figure 5A). We observed that on the early acute phase (9 dpi) NCz-SEGN24A+CpG group achieved the highest control of parasitemia. Moreover, when the area under the parasite-load curves were analyzed (Figure 5B), NCz-SEGN24A+CpG showed a significant reduction on the total parasite load compared with the control group, whereas the individual antigens Nt-Cz plus SEG24A+CpG conferred less protection.

More importantly, mice vaccinated with chimeric NCz-SEGN24A+CpG showed an increase in the survival rate compared to PBS group. Specifically, this group was the only one to maintain 100% survival rates, showing clear differences against the group of mice immunized with the individual antigens (60% survival for both Nt-Cz+SEG24A+CpG and control) (Figure 5C).

These results taken together manifest a clear advantage of administration of the chimeric NCz-SEGN24A plus CpG-ODN rather than immunizing with its individual domains, in terms of protection and survival against infection with *T. cruzi*.

**Chimeric NCz-SEGN24A Improves Protection Elicited by Nt-Cz Antigen**

As it was previously reported, immunization of mice with Nt-Cz plus CpG-ODN enhances protection conferred by vaccination with the full-length cruzipain or its C-terminal domain (17). To evaluate if vaccination with chimeric NCz-SEGN24A antigen would improve protection over the single *T. cruzi* antigen, we performed an immunization protocol where a group of
mice received Nt-Cz+CpG, and other group received NCz-SEGN24A+CpG (10 µg of each in both schemes).

After the last dose, animals were challenged with blood trypomastigotes of K98 clone, which belongs to a different DTU, TcI. On the acute phase of the infection, mice of both groups presented much lower amounts of circulating parasites (Figure 6A); at the peak of parasitemia (35 dpi), there were significant differences on the number of parasites for both groups against control ($p < 0.05$). However, when analyzing the areas under the total parasitemia curve, only mice immunized with NCz-SEGN24A+CpG presented significant reductions against control group in the total parasite loads ($p < 0.05$), with a 3-fold reduction of AUC (Figure 6B). Even though there was not a significant difference between AUC of Nt-Cz and NCz-SEGN24A groups, these results suggest an improvement in protection of the chimeric antigen vaccination over immunization with the single Nt-Cz antigen, which would be due to the inclusion of the superantigen domain in the chimera design.

DISCUSSION

Vaccination has proven to be the most successful strategy to stimulate systemic immune responses protecting against infection (42, 43). However, up to date, there are still many diseases for which there are no effective vaccines available. Among them, parasitic infections and particularly Chagas disease does not count yet with a vaccine generating sterilizing immunity (44).

In this work, with the aim to elicit a protective differential immune response against *T. cruzi*, we described a novel...
immunogen for vaccination purposes. We used a chimeric molecule that included a detoxified bacterial superantigen, which lacks its ability to bind to the TCR but retains the interaction with APCs, and an immunogenic domain of the T. cruzi antigen Cz. Thus, by mutation of one residue of major energetic contribution to TCR binding site (29), we obtained SEGN24A which showed...
non-significant increase in the frequency of mVβ8.2-bearing T cells in-vivo. In addition, by performing SPR assays, we observed a complete lack of interaction between SEGN24A and mVβ8.2. These results are in line with other authors’ publications, where removal of the ability of different SAgs to bind the TCR alone is enough to ablate the recruitment of T cells bearing particular Vβ TCRs, and thus, cell proliferative activities responsible for SAgs toxicity (45, 46).

Although SEGN24A lost its ability to stimulate T cells, as it was expected, it retained its capability to interact with macrophages similarly as SEGwt did. In accordance with this, SEGN24A would be able to promote a proinflammatory profile, which could determine a Th1 environment without the elimination of the T cell effective pool. With the aim to determine if SEGN24A induced a M1 profile when interacting with macrophagic cells, we performed assays using the murine cell line RAW 264.7. We observed that, both wild-type and mutant SEG reduced the proliferation rate of a macrophagic cell line and significantly stimulated nitrites secretion on the supernatant of these cells, characteristic of classical macrophagic activation. These results agree with previous publications (26), where different non-classical SAgs, including SEG, inhibited proliferation of human THP-1 cell line differentiated to macrophages, associated with cell death. As it was stated before, cell death could result in DAMPs release, favoring immune response stimulation, as it was previously described for other adjuvants (36, 37). Noli Truant et. al. (26) also reported that SAgs promoted on macrophages a proinflammatory cytokines response of M1 profile that also included nitrites production. Our results suggest that the mutant SEGN24A maintains the MHC-II binding capacity, activating biological responses on macrophages, though in a lesser extent compared to SEGwt. In a previous work, we demonstrated that SEG does not interfere with the viability of murine DCs (27) and the present results allow us to hypothesize that SEGwt and SEGN24A display similar behavior with mouse DCs, which needs to be further confirmed.

In the design of the heterologous chimeric construct were included the bacterial mutant SAg SEGN24A and the N-terminal domain of cruzipain (Cz), the major cysteine protease of T. cruzi. Our choice was based on previous publications of our group, where we demonstrated that Nt-Cz is the catalytic and protective domain of the enzyme. During natural infection with the parasite, C-terminal domain of Cz is immunodominant, eliciting high titers of specific antibodies. When immunizations are performed with the full-length Cz, immune responses are mostly directed against the C-terminal domain, which is poorly protective. In contrast, immunization with Nt-Cz redirects the immune response to the protective domain, avoiding distraction of the immune system, thereby enhancing protection (17). Other chimeric molecules have already been designed including the Nt-Cz domain, showing very promising results in terms of protection conferred against T. cruzi infection (18, 19).

As a proof of concept, the heterologous chimeric antigen NCz-SEGN24A was tested with different immunization protocols. First, we analyzed whether NCz-SEGN24A has intrinsic immunogenic properties. By immunizing mice with NCz-SEGN24A without the addition of adjuvants, systemic-antibody titers were obtained against the parasite antigen. However, for a parasite homologous chimeric immunogen that also included Nt-Cz, Traspain, no specific antibodies responses were evoked without the addition of adjuvants (Sanchez Alberti, unpublished results). Moreover, the profile of elicited antibodies in NCz-SEGN24A immunized mice indicated higher IgG2a than IgG1 specific profiles, indicating that the immune response was predominantly oriented by the Th1 subset, which is desirable in the design of vaccines against intracellular pathogens. Modest cellular responses were also elicited. These results suggest that NCz-SEGN24A could have self-adjuvanting properties which could be mediated by direct targeting to MHC-II on APCs, conferred by the superantigenic domain. Previous reports are in line with these findings, since conjugation of antigens to modified-superantigens promotes targeting to APCs by MHC-II binding and this improves antigen-specific immune responses (23, 46, 47). Nevertheless, further studies should be performed with NCz-SEGN24A, in order to prove this hypothesis.

The humoral and cellular responses triggered by NCz-SEGN24A immunization were translated into a tendency of reduction on parasite loads throughout the acute phase of the infection, after challenging mice with T. cruzi trypomastigotes. NCz-SEGN24A-immunized mice showed significant differences at the peak of parasitemia (35 dpi) compared to control, although the area under the total parasitemia curve (AUC) did not evidence statistical differences. Data points out that humoral responses toward the parasitic antigen are primed by immunization with NCz-SEGN24A alone. Nonetheless, since stronger cellular inductions are needed to control T. cruzi infection, the addition of adjuvants improves these responses.

Unmethylated synthetic CpG-ODNs have been widely used as adjuvants to improve humoral and cellular responses toward vaccine antigens, evidenced by several preclinical and clinical trials (48–50). In the current study, the inclusion of CpG-ODN potentiated humoral responses by inducing a ten-fold increase in IgG anti-Nt-Cz specific titers in mice immunized with NCz-SEGN24A; similar responses were obtained in mice immunized with both Nt-Cz and SEGN24A proteins. In addition, these immunizations displayed an IgG2a predominating isotype, accordingly with a Th1-oriented profile, and cellular responses were augmented when compared to adjuvantless NCz-SEGN24A immunization. Similar patterns of responses have been consistently reported by utilizing CpG-ODN for other antigens, including T. cruzi (13, 17, 35, 51–53). More importantly, sera samples from NCz-SEGN24A immunized mice were able to dramatically reduce the infection of Vero cells, compared with samples from PBS-vaccinated animals. These findings are in correspondence with former data showing highly significant inhibition of cell-invasion by sera from Nt-Cz+CpG immunized mice, whereas immunization with the C-terminal domain of Cz did not elicit a detectable inhibition (17). Thus, it could be inferred that subdominant B-cell epitopes capable of developing a high neutralizing activity are indeed retained in the chimeric NCz-SEGN24A protein. The promising results obtained using NCz-SEGN24A+CpG
prompted us to analyze the cellular immune response induced by this chimeric immunogen. Preliminary results, obtained with four immunizations of NCz-SEG24A+CpG, showed production of intracellular cytokines by CD4+ T cells. We observed differential intracellular levels of IFN-γ, TNF-α and IL-2 when compared with the control group immunized with PBS (unpublished results). Even though no specific CD8+ T cells activity was measured in this manuscript, a rich microenvironment in IL-2 would facilitate CD8+ T cell proliferation which would be essential to eradicate the infected cells. Since the dysfunction of the CD8+ T cell is a key to the persistence of *T. cruzi* in the murine model (54), functional CD8+ T cells (55, 56) could contribute to control the parasitemia in the chronic phase of the disease. Preliminary results carried out during the chronic phase of the disease suggest that mice immunized with four doses of NCz-SEG24A+CpG displayed an undetectable parasitemia, determined by quantitative real time PCR (unpublished data).

After *T. cruzi* challenge, both immunization groups reduced the parasite loads throughout the acute phase of the infection. Nonetheless, mice vaccinated with the chimeric antigen conferred significant differences against control when comparing the areas under the total parasitemia curve. NCz-SEG24A-immunized mice were also able to control parasitemia in the early days of the infection (9 dpi), which would be of particular relevance given the silent entry of the parasite and the consequent delayed generation of proper immune responses that allow the establishment of the infection (2, 57). Additionally, the NCz-SEG24A-immunized group maintained 100% survival until 75 dpi, showing a better performance in protection than Nt-Cz plus SEG24A group. We hypothesize that one of the reasons could be related to NCz-SEG24A differential intracellular pathway inside APCs, as it was previously shown for SEGwt (27), which would allow longer times of exposure of the parasitic antigen to T cells. Importantly, when immunizations were performed with the individual antigens, the molar doses of Nt-Cz and SEG24A were higher than those in chimeric NCz-SEG24A (10 μg of total protein were administered in each protocol), meaning that vaccination with NCz-SEG24A+CpG was more efficient at controlling parasitemia with lower amount of molecules of the specific parasite antigen.

When we compared NCz-SEG24A+CpG immunization vs. Nt-Cz+CpG, by performing a challenge with trypomastigotes from a different strain and DTU than the one we had used in the former experiment, NCz-SEG24A was the only group to show statistical differences in AUC against control. The chimeric antigen showed a clear protection in the assay performed, meaning that the inclusion of the SAg domain could indeed result advantageous. Furthermore, NCz-SEG24A was able to show a significant protection with lower molar doses of the Nt-Cz antigen, considering that in fact in the Nt-Cz+CpG group the molar dose was even double than in Nt-Cz+SEG24A+CpG group.

As a general conclusion, we were able to develop a novel heterologous immunogen including a bacterial superantigen which proved to be protective during the acute phase of the infection against *T. cruzi*. Protection was even extended toward *T. cruzi* strains belonging to different DTUs, although further analysis should be performed to better characterize immune response evoked by NCz-SEG24A antigen as well as extension of protection during the chronic phase. Our results highlight the importance of developing chimeric molecules and multicomponent vaccines against *T. cruzi* infection, with the aim of reducing parasitemia from the first stages of the infection, and we strongly believe that inclusion of modified bacterial superantigens are very promising in this field.

### DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

### ETHICS STATEMENT

The animal experiments (antisera production) were performed in accordance with the School of Medicine, Animal Ethics Committee (University of Buenos Aires) CD resolution #: 3381-18 Authorities for Animal Health of IMPaM, School of Medicine.

### AUTHOR CONTRIBUTIONS

MA, AS, AB, EM, and MMF conceived and designed the experiments. MA, AS, AB, EM, and MMF performed the experiments. MA, AS, AB, EM, and MMF analyzed the data. MA, EM, and MMF wrote the paper. All authors contributed to the article and approved the submitted version.

### FUNDING

This work was supported by the Grants from the Universidad de Buenos Aires (2018-2021 # 20020170100323BA) and Fundación Bunge & Born (2015-2017) destined to support neglected diseases studies.

### ACKNOWLEDGMENTS

We thank Carla Pascuale (Flow Cytometry unit, INBIRS, UBA-CONICET, Facultad de Medicina, UBA) and Sabrina Soldavini, Valeria Cardozo and Marianela Lewicki (Animal facilities and care IMPaM, Facultad de Medicina, UBA) for all the technical assistance.

### SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2020.01279/full#supplementary-material
REFERENCES

1. Ribeiro AL, Nunes MP, Teixeira MM, Rocha MOC. Diagnosis and management of Chagas disease and cardiomyopathy. Nat Rev Cardiol. (2012) 9:576–89. doi: 10.1038/nrcardio.2012.109

2. Nardy AF, Freire-de-lima CG, Morrot A. Immune evasion strategies of Trypanosoma cruzi. J Immunol. Res. (2015) 2015:78947. doi: 10.1155/2015/78947

3. Sales PA, Molina I, Murta SMF, Sánchez-Montalvá A, Salvador F, Corrêa-Oliveira R, et al. (2017). Experimental and clinical treatment of Chagas disease: a review. Am J Trop Med Hyg. 97, 1289–303. doi: 10.4269/ajtmh.16-0761

4. Bilate AM, Cunha-Neto E. Chagas disease cardiomyopathy: current concepts of an old disease. Rev Inst Med Trop Sao Paulo. (2008) 50:67–74. doi: 10.1590/S0036-46522008000200001

5. Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop. (2010) 115:22–7. doi: 10.1016/j.actatropica.2009.07.019

6. Hotz P. A handful of “antipoverty” vaccines exist for neglected diseases, but the world’s poorest billion people need more. Health Aff (2011) 30:1080–7. doi: 10.1377/hlthaff.2011.0317

7. Cazorla SI, Frank FM, Malchiodi EL. Vaccination approaches against Trypanosoma cruzi infection. Expert Rev Vaccines. (2009) 8:921–35. doi: 10.1586/erv.09.45

8. Bivona AE, Sanchez Alberti A, Cerny N, Trinitario S, Malchiodi EL. Chagas disease vaccine discovery. The search for a different immune reaction to antigen promotes pro-inflammatory cytokines, nitric oxide production and characterization of rSEA-EGF and CpG oligodeoxynucleotides for adjuvant development for vaccines: DAMPs and PAMPs as in vivo countermeasures. J Immunol (2020) 98:2346–44. doi: 10.1186/s41541-017-00128-0

9. Laderach D, Cerban F, Motran C, De Cima EV, Gea S. Trypanosoma cruzi: The major cysteinyll proteinase (cruzipain) is a relevant immunogen of parasite acidic antigens (FIII). Int J Parasitol. (1996) 26:1249–54. doi: 10.1016/S0166-0939(96)00099-9

10. Zúñiga E, Montes C, Barbieri G, Gruppi A. Antibodies against Trypanosoma cruzi alkaline antigens are elicited in sera from acute but not chronic human chagasic patients. Clin Immunol. (1999) 93:81–9. doi: 10.1006/clim.1999.4744

11. Schnapp AR, Eickhoff CS, Scharfstein J, Hoft DF. Induction of B- and T-cell responses to cruzipain in the murine model of Trypanosoma cruzi infection. Microbes Infect. (2002) 4:805–13. doi: 10.1016/S1286-4579(02)01600-3

12. Schnapp AR, Eickhoff CS, Sizemore D, Curtis R, Hoft DF. Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice. Infect Immun. (2002) 70:5605–4. doi: 10.1128/IAI.70.5605-70.2002

13. Frank FM, Petray PB, Cazorla SI, Muñoz MC, Corral RS, Malchiodi EL. Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypanomastigotes. Vaccine. (2003) 21:77–86. doi: 10.1016/S0264-410X(03)00543-3

14. Guíñazú N, Pellegrini A, Carrera-Silva EA, Aoki MP, Cote R, et al. Mucosal heterologous prime/boost vaccination induces polyfunctional monocytes/macrophages inducing cell death and inefficient activation. Front Immunol. (2010) 98:1260–9. doi: 10.4049/immunol.182.3.1260

15. Sanz-Díaz D, Ingelmo M, Rosales L, et al. Engineered trivalent immunogen adjuvanted with a STING agonist protects against a lethal challenge with trypomastigotes. J Infect Dis. (2018) 217:153303818762910. doi: 10.1093/infdis/jiy086

16. Corrêa-Oliveira R, et al. Engineered trivalent immunogen adjuvanted with a STING agonist protects against a lethal challenge with trypomastigotes. J Infect Dis. (2018) 217:153303818762910. doi: 10.1093/infdis/jiy086

17. Sanchez Alberti A, Bivona AE, Matsos MN, Gómez MA, Guzmán CA, Malchiodi L. Tc52 amino-terminal-domain DNA carried by attenuated salmonella enterica serovar typhimurium induces protection against a Trypanosoma cruzi lethal challenge. Infect Immun. (2014) 82:4265–75. doi: 10.1128/IAI.02190-14

18. Bivona AE, Sanchez Alberti A, Matsos MN, Cerny N, Cardoso AC, Morales C, et al. Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for chagasic disease vaccine. PLoS Negl Trop Dis. (2018) 12:e0006384. doi: 10.1371/journal.pntd.0006384

19. Miyaji EN, Carvalho E, Oliveira MLS, Raw I, Ho PL. Trends in adjuvant development for vaccines: DAMPs and PAMPs as
potential new adjuvants. *Braz J Med Biol Res.* (2011) 44:500–13. doi: 10.1590/S0100-879X2011000600003

37. Svensson A, Sandberg T, Siesjo P, Eriksson H. Sequestering of damage-associated molecular patterns (DAMPs): a possible mechanism affecting the immune-stimulating properties of aluminium adjuvants. *Immunol. Res.* (2017) 65:164–75. doi: 10.1007/s12026-017-8972-5

38. Bode C, Zhao G, Steinhaugen F, Kinjo T, Klimman DM. CpG DNA as a vaccine adjuvant. *Expert Rev Vaccines.* (2011) 10:499–511. doi: 10.1586/erv.10.174

39. Scheirermann J, Klimman DM. Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. *Vaccine.* (2014) 32:6377–89. doi: 10.1016/j.vaccine.2014.06.065

40. Ibáñez AE, Coria LM, Carabajal MV, Delpino MV, Risso GS, Bruno L, Carabajal MV et al. A brucella spp. prostate inhibitor limits antigen lysosomal proteolysis, increases cross-presentation, and enhances CD8+ T cell responses. *J Immunol.* (2016) 196:4014–29. doi: 10.4049/jimmunol.1501188

41. Rueckert C, Guzmán CA. Vaccines: from empirical development to rational design. *PLoS Pathog.* (2012) 8:e1003001. doi: 10.1371/journal.ppat.1003001

42. Scheer CM, Gillespie PM, Hotez PJ, Bottazzi ME. New vaccines for neglected parasitic diseases and dengue. *Vaccine Immunol.* (2014) 23:1–7. doi: 10.1016/j.vaccine.2014.05.011

43. Andreado E, D’Oro U, Rappuoli R, Finco O. Vaccine evolution and its application to fight modern threats. *Front Immunol.* (2019) 10:1722. doi: 10.3389/fimmu.2019.01722

44. Beaumier CM, Gillespie PM, Hotez PJ, Bottazzi ME. New vaccines for neglected parasitic diseases and dengue. *Transl. Res.* (2013) 162:144–55. doi: 10.1016/j.trsl.2013.03.006

45. Hu D-L, Omoe K, Sasaki S, Sashinami H, Sakuraba H, Yokomizo Y, et al. Vaccination with nontoxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus infection. *J Infect. Dis.* (2003) 188:743–52. doi: 10.1086/377038

46. Radcliff FJ, Loh JMS, Ha B, Schuhbauer D, McCluskey J, Fraser JD. Antigen targeting to major histocompatibility complex class II with streptococcal mitogenic exotoxin Z-2 M1, a superantigen-based vaccine carrier. *Clin Vaccine Immunol.* (2012) 19:574–86. doi: 10.1128/CVI05446-11

47. McIntosh JD, Manning K, Chokshi S, Naoumov NV, Fraser JD, Dunbar PR, et al. An engineered non-toxic superantigen increases cross-presentation of hepatitis B virus nucleocapsids by human dendritic cells. *PLoS ONE.* (2014) 9:e93598. doi: 10.1371/journal.pone.0093598

48. Halperin SA, Van Nest G, Smith B, Abtahi S, Whiley H, Eiden JJ. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. *Vaccine.* (2003) 21:2461–7. doi: 10.1016/S0264-410X(03)00045-8

49. Hopkins RJ, Daczkowski NF, Kaptu PE, Muse D, Sheldon E, LaForce C, et al. Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of anthrax vaccine adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers. *Vaccine.* (2013) 23:1–7. doi: 10.1016/j.vaccine.2013.04.063

50. Rynkiewicz D, Rathkopf M, Sim I, Waytes AT, Hopkins RJ, Giri L, et al. Marked enhancement of the immune response to BioThrax® (anthrax vaccine adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers. *Vaccine.* (2011) 29:6313–20. doi: 10.1016/j.vaccine.2011.05.047

51. Corral RS, Petray PB. CpG DNA as a Th1-promoting adjuvant in immunization against Trypanosoma cruzi. *Vaccine.* (2000) 19:234–42. doi: 10.1016/S0264-410X(00)00172-9

52. Matos MN, Sánchez Alberti A, Cazorla SI, Malchiodi EL. A prime-boost immunization with Tc52 N-terminal domain DNA and the recombinant protein expressed in *Pichia pastoris* protects against Trypanosoma cruzi infection. *Vaccine.* (2016) 34:3243–51. doi: 10.1016/j.vaccine.2016.05.011

53. Matos MN, Cazorla SI, Schulze K, Ebensen T, Guzmán CA, Malchiodi EL. Immunization with Tc52 or its amino terminal domain adjuvanted with c-di-AMP induces Th17+Th1 specific immune responses and confers protection against *Trypanosoma cruzi*. *PLoS Negl Trop Dis.* (2017) 11:e0005300. doi: 10.1371/journal.pntd.0005300

54. Pack AD, Collins MH, Rosenberg CS, Tarleton RL. Highly competent, non-exhausted CD8+ T cells continue to tightly control pathogen load throughout chronic *Trypanosoma cruzi* infection. *PLoS Pathog.* (2018) 14:e1007410. doi: 10.1371/journal.ppat.1007410

55. Bachmann MF, Wollant P, Walton S, Schwarz K, Oxenius A. Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections. *Eur J Immunol.* (2007) 37:1502–12. doi: 10.1002/eji.200637023

56. Badovinac VP, Porter BB, Harty JT. CD8+ T cell contraction is controlled by early inflammation. *Nat Immunol.* (2004) 5:809–17. doi: 10.1038/nij1098

57. Padilla AM, Simpson LJ, Tarleton RL, Padilla AM, Simpson LJ, Tarleton RL. Insufficient TLR activation contributes to the slow development of CD8+ T cell responses in *Trypanosoma cruzi* infection. *J Immunol.* (2009) 183:1245–52. doi: 10.4049/jimmunol.0901178

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.